On 30 October 2024, the US Food and Drug Administration (FDA) provided an update on its drug shortage database, reporting that all doses of Novo Nordisk’s popular weight loss injection Wegovy® and diabetes drug Ozempic® (both of which comprise semaglutide) are now available in the US. This demonstrates Novo Nordisk’s ability to increase supply amid growing demand.
Novo Nordisk stated to US media that all doses are now shipped regularly to wholesalers, thanks to expanded manufacturing capacity and close communication with the FDA. Novo Nordisk emphasised a gradual supply increase to ensure patient care and track prescribing trends.